Rafael Holdings, Inc. (RFL) - 10-K Summary
Business Context and Reporting Period
Company: Rafael Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended July 31, 2025
Business Overview: A biotechnology company developing pharmaceuticals and holding interests in clinical/early-stage companies. The primary focus is the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The company operates through three segments: Healthcare, Infusion Technology, and Real Estate.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Revenue | $917 | $637 |
| Net Loss (Consolidated) | $(30,643) | $(65,003) |
| Net Loss Attributable to RFL | $(30,520) | $(34,410) |
| Cash and Cash Equivalents (End of Period) | $52,769 | $2,675 |
| Operating Cash Flow | $(18,924) | $(7,802) |
| Total Assets | $114,109 | $96,832 |
| Total Liabilities | $15,738 | $10,574 |
Note: The filing text does not provide explicit gross margin or operating margin percentages; however, the company reported a consolidated loss from operations of $(29,159) thousand for 2025 compared to $(102,627) thousand for 2024.
Material Changes vs. Prior Period
- Cyclo Merger: On March 25, 2025, the company consummated a merger with Cyclo Therapeutics, making it a wholly-owned subsidiary. This added $515 thousand in product revenue and significantly increased R&D expenses ($8.4 million) and G&A expenses ($3.6 million) in the Healthcare segment.
- Goodwill Impairment: Recorded a $3.1 million impairment charge related to the Infusion Technology segment (Day Three Labs) due to operational reductions and layoffs.
- Capital Raise: Completed a $25 million Rights Offering in June 2025, with the controlling shareholder, Howard S. Jonas, purchasing the unsubscribed portion. This significantly increased cash reserves from $2.7 million to $52.8 million.
- Asset Sales: Day Three Labs Manufacturing sold assets and licensed technology for a $500,000 convertible note and milestone payments. Cornerstone sold rights to telaglenastat for a modest upfront payment.
- Loss Reduction: Consolidated net loss decreased by 53% year-over-year, primarily driven by the absence of a $89.9 million in-process research and development (IPR&D) expense recorded in 2024 related to the Cornerstone acquisition.
Guidance, Outlook, and Risks
- Clinical Outlook: The pivotal Phase 3 trial for Trappsol® Cyclo™ (TransportNPC) has fully enrolled 94 patients. An interim analysis in June 2025 concluded the drug was well-tolerated, and the Data Monitoring Committee recommended continuing the study to the full 96 weeks.
- Regulatory Risks: The Rare Pediatric Disease Priority Review Voucher (PRV) program, which could provide significant value upon approval, is subject to statutory sunset provisions. Unless reauthorized, no PRVs can be awarded for approvals after September 30, 2026.
- Geopolitical Risks: Operations in Israel (LipoMedix, Day Three, Real Estate) face risks from regional instability, including the war in Gaza and the June 2025 conflict with Iran, which may disrupt operations and personnel availability.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting at Cyclo related to accruals and expense recognition following the merger. A remediation plan is underway.
- Liquidity: Management expects cash reserves of $52.8 million to be sufficient to meet obligations for at least the next 12 months.
Key Facts for Investor Verification
- Phase 3 Trial Status: Verify the timeline for the final analysis of the TransportNPC Phase 3 trial and the subsequent regulatory filing strategy.
- PRV Program Status: Monitor legislative developments regarding the reauthorization of the Rare Pediatric Disease Priority Review Voucher program, as its expiration could impact the valuation of the lead asset.
- Remediation of Material Weakness: Confirm the implementation and effectiveness of the remediation plan for the internal control weakness identified at Cyclo.
- Day Three Segment Viability: Assess the impact of the $3.1 million goodwill impairment and the asset sale on the future revenue potential of the Infusion Technology segment.
- Geopolitical Exposure: Evaluate the specific operational impacts of the ongoing conflict in Israel on the company's Israeli-based subsidiaries and real estate assets.